ФАРМАКОЭПИДЕМИОЛОГИЯ ВА УНИНГ АМАЛИЙ ТИББИЁТДАГИ ЎРНИ

8. Hartzema A.G., Tilson H.H., Chan K.A. The contribution of pharmacoepidemiology to the study of drug uses and effects, and risk management // Hartzema A.G., Tilson H.H., Chan K.A.; editors. Pharmacoepidemiology and therapeutic risk assessment. – Cincinnati: Harvey Whitney Books, 2008. – P. 1-38.

9. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women // New Engl. J. Med. – 1971. – Vol. 284. – P. 878-881

10. Jick H., Rodriguez L.A.G., Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects // Lancet. – 1998. – Vol. 352. – P. 1767-1770

11. Kennedy D. Assessing national drug utilization in the United States. WHO Drug Utilization Research Group Meeting. – Washington, 1983.

12. Lee D., Bergman U. Studies of drug utilization. In: Strom B.L., editor. Pharmacoepidemiology. – 2nd ed. – N. York: John Wiley & Sons, Inc., 1994. – P. 379-395.

13. Lee J.A.H., Draper P.A., Weatherall M. Prescribing in three English towns // Milbank Mem. Fund. Q. – 1965. – Vol. 43. – P. 285-290.

14. McBride W.G. Thalidomide and congenital abnormalities // http://medsport.uz 35 Lancet. – 1961. – Vol. 2. – P. 1358.

15. Meade T.W. Prescribing of chloramphenicol in general practice // Brit. Med. J. – 1967. – Vol. 1. – P. 671-674.

16. Neutel C.I. The status of pharmacoepidemiology in a regulatory environment // Pharmacoepidemiol. Drug Saf. – 2000. – Vol. 9. – 65-70.

17. Porta M.S., Hartzema A.G. The contribution of epidemiology to the study drugs // Drug Int. Clin. Pharm. – 1987. – Vol. 21. – P. 741-747.

18. Ronning M. Setting-up the WHO ATC classification of drugs and the Defined Daily Dose – problems and potential for standardizing drug use research worldwide // McGavock H.; editor. Handbook of Drug Use Research Methodology. – 1st ed. – Newcastle: The United Kingdom Drug Utilization Research Group, 2000. – P. 1-9

19. Serradel J.S., Bjornson D.C., Hartzema A.G. Drug utilization study methodologies: national and international perspectives // Drug Int. Clin. Pharm. – 1987. – Vol. 21. – P. 994-1001.

20. Spitzer W.O., Lewis M.A., Heinemann L.A.J. et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study // Brit. Med. J. – 1996. – Vol. 312. – P. 83-88.

21. Strom B.L. Study designs available for pharmacoepidemiology studies // Strom B.L.; editor. Pharmacoepidemiology. – 3d ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 17-30.

22. Strom B.L. What is pharmacoepidemiology? // Strom B.L.; editor. Pharmacoepidemiology. – 3d ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 3-16.

23. Strom B.L. When should one perform pharmacoepidemiology studies? // Strom B.L.; editor. Pharmacoepidemiology. – 3nd ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 63-72.

24. Tilson H.H. Pharmacoepidemiology: the future // Drug Int. Clin. Pharm. – 1988. – Vol. 22. – P. 416-421. 32

25. Urquhart J. Role of pharmacoepidemiology in drug development // Int. J. Clin. Pharm., Ther. Toxicol. – 1992. – Vol. 30. – P. 456-458.

26. Van Boxtel C.J. Wang G. Some observations on pharmacoepidemiology in Europe // Nethelands J. Med. – 1997. – Vol. 51. – P. 205-212.

27. Verhamme K., Sturkenboom M. Study designs in paediatric pharmacoepidemiology // Europ. J. Clin. Pharmacol. – 2011. – Vol. 67. №1. – P. 67-74.28

28. Wettermark B. The intriguing future of pharmacoepidemiology // Europ. J. Clin. Pharmacol. – 2013. – Vol. 69, №1. – P. 43-51.

29. WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden // Europ. J. Clin. Pharmacol. – 1985. – Vol. 29. – P. 1-8.

30. Wilson-Davis K. Study design and the use of statistics in drug use research // McGavock H.; editor. Handbook of Drug Use Research Methodology. – 1st ed. – Newcastle: The United Kingdom Drug Utilization Research Group, 2000. P. 36-55.

31. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraception: results of international multicentre case-control study // Lancet. – 1995. – Vol. 346. – P. 1575-1582

32. World Health Organization Expert Committee. The selection of essential drugs. – Geneva: World Health Organization, 1977.

33. Wright P. Untoward effects associated with practolol administration. Оculo-mucocutaneous syndrome // Brit. Med. J. – 1975. – Vol. 1. – P. 595-598

1. Флетчер Р., Флетчер С., Вагнер Е. Клиническая эпидемиология. Основы доказательной медицины. – 3-е изд./ Пер. с англ.; Под ред. С.Е. Бащинского, С.Ю. Варшавского. – М.: Медиа Сфера, 1998.

2. Anonymous (Boston Collaborative Drug Surveillance Program). Regular aspirin intake and acute myocardial infarction // Brit. Med. J. – 1974. – Vol. 1. – P. 440-443.

3. Bombardier C. Research challenges; overview of epidemiological study design // J. Reumatol. – 1998. – Vol. 15 (Suppl 17). – P. 5-8.

4. Brodie D.C. Drug utilization review: planning // Hospitals. – 1972. – Vol. 46. – P. F03-12.

5. Einarson T.R., Bergman U., Wiholm B.-E. Principles and practice of pharmacoepidemiology // Speight T.M., Holford N.H.G.; editors. Avery’s Drug Treatment. – 4th ed. – New Zealand: Adis International Limited, 1997. – P. 371-392.

6. Hartzema A.G. Pharmacoepidemiology - its relevance to clinical practice // J. Clin. Pharm. Ther. – 1992. – Vol. 17. – P. 73-74.

7. Hartzema A.G., Porta M.S., Tilson H.H. Pharmacoepidemiology: an introduction. – 2nd ed. – Cincinnati: Harvey Whitney Books, 1991